The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023SUPPLEMENT | CMA as a Means to Counteract Alpha-synuclein Pathology in Non-human Primates”
Study Rationale: One of the main pathways to remove excess amounts of the alpha-synuclein protein that is linked to Parkinson’s disease (PD) is the lysosomal chaperone-mediated autophagy (CMA) pathway...
-
Therapeutics Development Initiative, 2011Dopamine D1 Positive Modulators for the Treatment of Parkinson's Disease
Objective/Rationale:
L-DOPA is the standard treatment of Parkinson’s disease (PD) but prolonged use results in dyskinesia. D2 agonists often require L-DOPA supplementation and can cause side effects... -
Therapeutics Development Initiative, 2008Development of ERb agonists for the treatment of Parkinson's Disease
Objective/Rationale:
Estrogens modulate many cerebral functions such as mental state, mood, cognition and locomotion. Data indicate that estrogens may slow down the development and progression of PD... -
Rapid Response Innovation Awards, 2007Virtual Reality to Reduce Fall Risk in Patients with Parkinson’s Disease
Objective/Rationale:
Virtual Reality (VR) allows for training in complex environments, while motivating subjects to perform numerous repetitions of the training tasks under well-controlled conditions... -
Therapeutic Pipeline Program, 2015Effects of Transcranial Stimulation on Freezing of Gait in Parkinson's Disease
Study Rationale:
Many people with Parkinson's disease experience freezing of gait, when the person is unable to move forward, despite his or her best efforts. Although it is not exactly clear why or... -
Rapid Response Innovation Awards, 2014Neuroimaging Carriers of the Alpha-synuclein E46K Mutation as a Model of Idiopathic Lewy Body Disease
Study Rationale:
In 2004 our group described, for the first time in literature, the E46K mutation of the alpha-synuclein gene in a family from the Basque region of Spain. The rare E46K mutation is...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.